文献速递急性肾损伤肾小球疾病血液净化与透析

COVID-19感染与疫苗接种相关血栓性微血管病的个体患者数据系统综述

Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination-Associated Thrombotic Microangiopathy.
PubMed 文献 · Kidney Int Rep · 2024-08-08

该系统综述与荟萃分析纳入118项研究共170例患者,其中aHUS84例、TTP86例,分别与COVID-19感染或疫苗接种相关。感染后aHUS病例显著多于疫苗接种后,而TTP则相反;aHUS合并3期AKI者约四分之三需肾脏替代治疗,TTP中重症COVID-19预测未缓解或死亡,利妥昔单抗和caplacizumab显示保护作用。

要点

  • COVID-19感染更常触发aHUS,疫苗接种更常触发TTP。
  • aHUS合并3期AKI者约四分之三需肾脏替代治疗,中位15。
  • TTP中重症COVID-19预测未缓解或死亡,利妥昔单抗和caplacizumab有保护趋势。

核心结论

  • COVID-19感染和疫苗接种是aHUS和TTP发病或复发的潜在触发因素,尤其见于未使用维持性补体抑制剂或免疫抑制的患者。

研究设计与样本

  • 遵循PRISMA更新指南的系统综述与荟萃分析,检索PubMed的病例报告和系列,最终纳入118项研究共170例患者。

主要发现

  • 队列包括84例aHUS和86例TTP,由COVID-19感染(n=92)或疫苗接种(n=78)引起。
  • 感染后aHUS病例(n=65)显著多于免疫接种后(n=19),而TTP则相反(分别为n=27和n=59;P<0.001)。
  • aHUS合并3期AKI患者中约四分之三需要肾脏替代治疗,中位15。
  • TTP患者中重症COVID-19感染(P=0.04)预测末次随访时未缓解或死亡。
  • 使用静脉利妥昔单抗和caplacizumab具有保护作用(分别为P=0.03和P=0.06)。

关键数值与推荐

  • 末次随访不良结局定义为eGFR<30 ml/min per 1.73 m2(aHUS患者)、治疗未缓解或患者死亡。
  • mRNA疫苗后免疫性TTP报告比例高于HUS(81% vs. 58%;P=0.06)。

临床怎么用

  • 对COVID-19感染或疫苗接种后出现TMA的患者,应警惕aHUS或TTP,尤其未使用补体抑制剂或免疫抑制者。
  • aHUS合并3期AKI时需准备肾脏替代治疗;TTP中重症COVID-19提示预后不良,可考虑利妥昔单抗和caplacizumab治疗。

局限性

  • 基于病例报告和系列的系统综述,可能存在发表偏倚和报告不完整。
  • 样本量有限,部分比较的P值接近显著性阈值,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sporadic cases of atypical hemolytic uremic syndrome (aHUS) have been described in the literature in association with COVID-19 infection and vaccination in adults and pediatric patients. The exact mechanisms underlying COVID-19-associated thrombotic microangiopathies (TMAs) remain incompletely understood. Herein, we present a detailed meta-analysis of the clinical characteristics, outcomes, and management strategies of COVID-19-associated aHUS and thrombotic thrombocytopenic purpura (TTP). METHODS: This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses updated guidelines. PubMed was utilized for searching for case reports and series. Adverse outcome at last follow-up was defined as estimated glomerular filtration rate < 30 ml/min per 1.73 m2 (patients with aHUS), no remission with therapy, or patient death. Data were analyzed using Wilcoxon rank and Chi-square tests. RESULTS: Our analysis cohort included 118 studies reporting on 170 patients. These included 84 cases of aHUS and 86 cases of TTP resulting from COVID-19 infection (n = 92) or vaccination (n = 78). Significantly more cases of aHUS were reported after infection (n = 65) than immunization (n = 19), compared to TTP, where the reverse was true (n = 27 and n = 59, respectively; P < 0.001). In patients with aHUS with stage 3 acute kidney injury (AKI), requirement of kidney replacement therapy (KRT) was seen in three-fourths of the cohort for a median of 15. In patients with TTP, severe COVID-19 infection (P = 0.04) predicted nonremission or death at last follow-up. Administration of i.v., rituximab and caplacizumab were protective (P = 0.03 and P = 0.06, respectively). Immune TTP (iTTP) was reported more often than HUS following mRNA vaccines (81% vs. 58%; P = 0.06). CONCLUSION: COVID-19 infection and vaccination are a potential trigger for onset or relapse of aHUS and TTP, especially in patients who are not on maintenance complement inhibitors or immunosuppression.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Moradiya P, Khandelwal P, Raina R, et al. Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination-Associated Thrombotic Microangiopathy. Kidney Int Rep. 2024. PMID: 39534187. doi:10.1016/j.ekir.2024.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。